Last updated: February 24, 2026
What is NDC 63323-0125?
NDC 63323-0125 identifies a specific drug product, likely a biologic or biosimilar. Based on available data, this NDC corresponds to a biosimilar of reference biologics used in oncology or autoimmune indications. The precise product name is "Erelzi" (etanercept), a biosimilar of Enbrel (etanercept) used for rheumatoid arthritis, psoriasis, and other inflammatory conditions.
Market Landscape
Product Indication and Market Penetration
- Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa.
- Market Size: The biologic disease-modifying antirheumatic drugs (bDMARDs) market was valued at approximately $60 billion in 2022, with biosimilars accounting for roughly 15% ($9 billion).
- Regulatory Approvals: Erelzi received FDA approval in August 2016. It maintains a competitive positioning against entrenched biologics like Enbrel, Amgen's Eticava (biosimilar of etanercept), and other biosimilars entering the market.
- Market Penetration: Biosimilars of etanercept hold about 20-30% of the U.S. etanercept market, with wholesale acquisition prices (WAP) about 30-40% lower than the reference product.
Key Competitors
| Product Name |
Manufacturer |
Approval Year |
Competition Level |
Price Discount |
| Enbrel (reference) |
Amgen |
1998 |
Market leader |
n/a |
| Erelzi (ND: 63323-0125) |
Sandoz |
2016 |
Moderate |
30-40% lower |
| Eticava (biosimilar) |
Amgen |
2018 |
Moderate |
Similar to Erelzi |
| Benepali (biosimilar) |
Biogen |
2018 |
Limited in U.S. |
30% less than Enbrel |
Market Drivers
- Patent expirations for Enbrel in 2029 open additional opportunities.
- Increasing biosimilar adoption driven by cost pressures in healthcare.
- Expanded indications and prescribing confidence.
Market Challenges
- Prescriber hesitance toward biosimilars.
- Limited insurance rebates for biosimilars compared to reference biologics.
- Regulatory barriers in certain regions, impacting global sales.
Price Projections
Current Pricing Dynamics
- U.S. wholesale prices for Erelzi are approximately $8,000 to $9,000 per year per patient.
- Biosimilar versions like Erelzi price at $5,000 to $6,000 per year, representing a 33-40% discount.
- Specialty pharmacies or infusion centers often negotiate further discounts based on volume.
Short-term Price Projections (Next 1-3 Years)
| Year |
Estimated Wholesale Price |
Key Factors influencing price |
| 2023 |
$5,500 - $6,000 |
Stable, with minor discounts due to market saturation |
| 2024 |
$5,200 - $5,800 |
Competitive pressure increases |
| 2025 |
$4,800 - $5,500 |
Entry of additional biosimilars reduces prices further |
Long-term Price Trends (Next 5+ Years)
- Potential Decrease: Biosimilar prices could decline by an additional 15-25% with increased market penetration.
- Market Maturation: Prices for biosimilars of etanercept could stabilize around $4,000 to $4,500 per year.
- Global Market Variance: External factors such as regulatory changes and healthcare policies could impact prices. E.g., Europe sees a sustained biosimilar price reduction to approximately 20% lower than the reference.
Price Sensitivity Analysis
- High Adoption Scenario: If biosimilar market share reaches 50% by 2026, prices could fall to $4,200.
- Low Adoption Scenario: Resistance to biosimilars sustains prices at $5,500+.
Regulatory and Policy Impact
- U.S.: CMS and Medicaid promote biosimilar substitution, affecting pricing and market share.
- EU: Longer biosimilar market history demonstrates price reductions and increased prescribing confidence.
- Potential Policy Changes: Legislation promoting biosimilar substitution and pricing transparency could accelerate price declines.
Conclusion
NDC 63323-0125, identified as Erelzi biosimilar, operates in a competitive, price-sensitive market. Current prices hover around $5,500–$6,000/year, with potential reductions driven by increased adoption, patent expirations, and policy initiatives. Price declines of 15-25% over five years are plausible, with market share growth primarily influenced by prescriber acceptance and payer policies.
Key Takeaways
- Biosimilar NDC 63323-0125 competes primarily against Enbrel and other biosimilars.
- The current wholesale price is approximately $5,500 to $6,000 annually.
- Prices are expected to decline by 15-25% over five years with increased market penetration.
- Regulatory policies will significantly influence market dynamics and pricing.
- Biologics' expanding indications could sustain or grow demand, offsetting price pressures.
Frequently Asked Questions
-
When will biosimilar NDC 63323-0125 face major patent expiration impacts?
Patent protection for the reference product Enbrel expires in 2029, likely opening more biosimilar market opportunities shortly thereafter.
-
What is the primary driver of biosimilar adoption in the U.S.?
Cost savings for payers and institutions, along with evolving regulatory pathways and prescriber confidence.
-
How does biosimilar pricing compare globally?
Prices tend to be lower in Europe, often about 20% less than the U.S., due to different reimbursement and regulatory systems.
-
What risks could affect future price projections?
Healthcare policy changes, patent litigation, or accelerated biosimilar approvals could influence market timing and pricing.
-
What is the outlook for biosimilar market share?
Growth from 20-30% currently could reach over 50% by 2026, depending on prescriber acceptance and payer incentives.
Sources:
[1] IQVIA. (2022). Global Biologics and Biosimilars Market Report.
[2] FDA. (2016). Approval of Erelzi.
[3] NICE. (2022). Biosimilar Medicines in the UK.
[4] EvaluatePharma. (2023). Oncology and Autoimmune Biosimilars Market Outlook.
[5] Centers for Medicare & Medicaid Services. (2022). Biosimilars and Cost Savings.
